Q4 25 EPS
$-0.03
BEAT +46.43%
Est. $-0.06
Q4 25 Revenue
$19.2M
BEAT +0.21%
Est. $19.1M
vs S&P Since Q4 25
-3.5%
TRAILING MARKET
APYX +10.7% vs S&P +14.2%
Full Year 2025 Results
FY 25 EPS
$-0.27
BEAT +11.18%
Est. $-0.30
FY 25 Revenue
$52.8M
BEAT +1.19%
Est. $52.2M
Market Reaction
Did APYX Beat Earnings? Q4 2025 Results
Apyx Medical closed out fiscal 2025 on a strong note, delivering a Q4 that beat Wall Street expectations on both the top and bottom lines as the commercial momentum behind its AYON Body Contouring System continued to build. The company posted revenue… Read more Apyx Medical closed out fiscal 2025 on a strong note, delivering a Q4 that beat Wall Street expectations on both the top and bottom lines as the commercial momentum behind its AYON Body Contouring System continued to build. The company posted revenue of $19.16 million for the quarter, a 34.8% increase year-over-year that edged past the $18.54 million consensus estimate by 3.35%, while its net loss of $0.03 per share came in well ahead of the $0.06 loss analysts had anticipated, a 46.43% positive surprise. The primary engine behind the outperformance was the Surgical Aesthetics segment, which grew 38.1% year-over-year to $16.71 million following AYON's September 2025 commercial launch, with U.S. Sales alone surging nearly 50%. Adjusted EBITDA turned positive at $689,000, a meaningful inflection from a $2.20 million loss a year earlier. Looking ahead, management guided fiscal 2026 total revenue of $57.50 million to $58.50 million, with Surgical Aesthetics expected to carry the bulk of growth as a potential mid-2026 FDA clearance for AYON's power liposuction label expansion could further broaden the system's commercial reach.
Key Takeaways
- • Commercial launch of AYON Body Contouring System in September 2025 driving U.S. Surgical Aesthetics sales growth of nearly 50%
- • Strong international generator sales contributing to Surgical Aesthetics growth
- • Disciplined cost management keeping operating expenses flat year-over-year in Q4
- • Favorable segment mix shift toward higher-margin Surgical Aesthetics
APYX YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
APYX Revenue by Segment
With YoY comparisons, source: SEC Filings
APYX Revenue by Geography
With YoY comparisons, source: SEC Filings
“We are making steady progress scaling the U.S. commercial program for AYON following its official launch in September 2025, with early customer interest and order activity continuing to exceed our internal expectations. This momentum contributed to more than 38% growth in our Surgical Aesthetics segment, including a nearly 50% increase in the U.S. market.”
— Charlie Goodwin, Q4 2025 Earnings Press Release
APYX Earnings Trends
APYX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
APYX EPS Trend
Earnings per share: estimate vs actual
APYX Revenue Trend
Quarterly revenue: estimate vs actual
APYX Quarterly Results
6 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $-0.08 | $-0.07 | +14.63% | $13.9M | +5.38% |
| Q1 26 BEAT | $-0.10 | $-0.05 | +50.00% | $12.5M | +9.13% |
| Q4 25 BEAT FY | $-0.06 | $-0.03 | +46.43% | $19.2M | +0.21% |
| FY Full Year | $-0.30 | $-0.27 | +11.18% | $52.8M | +1.19% |
| Q3 25 BEAT | $-0.10 | $-0.05 | +51.22% | $12.9M | +7.30% |
| Q2 25 BEAT | $-0.09 | $-0.09 | +0.00% | $11.4M | -2.79% |
| Q1 25 BEAT | $-0.12 | $-0.10 | +13.04% | $9.4M | +1.04% |